vimarsana.com

Page 480 - வர்த்தகம் செய்யப்பட்டது ப்ராடக்ட்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NFL Insider Reveals Patriots Plan A For QB Next Season | Talk Radio 105 9

Noble REMC hits new Operation Round Up milestones

Patriots Re-Acquire Former Starter From Last Super Bowl Season Via Trade

NFL Insider Reveals Patriots Plan A For QB Next Season | Newsradio WOOD 1300 and 106 9 FM

B C s Eupraxia Pharmaceuticals sees lacklustre trading debut

The Globe and Mail Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer Eupraxia Pharmaceuticals Inc. stock had a lacklustre debut Tuesday after it completed the first TSX-only initial public offering by a Canadian biotechnology company in 18 years. The Victoria-based company’s stock began trading after raising $41-million at a price of $8 per unit, consisting of one share and half of a warrant. Each warrant gives investors the right to buy a share of Eupraxia at $11.20 for five years. Eupraxia is developing a treatment for knee pain from osteoarthritis that adds a time-release polymer coating to an established anti-inflammatory steroid.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.